Key terms
About MNPR
Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest MNPR news
Apr 16
8:13am ET
Monopar Therapeutics Advances Radiopharmaceuticals with New Patent
Apr 16
8:08am ET
Monopar Therapeutics announces filing of patent protecting MNPR-101
Apr 11
7:25am ET
Monopar Therapeutics upgraded to Buy from Hold at JonesResearch
Mar 28
7:02am ET
Monopar Therapeutics reports Q4 EPS (12c) vs (22c) last year
Mar 07
8:42am ET
Monopar Therapeutics Unveils Radiopharma Advances Online
Mar 05
7:12am ET
Monopar Therapeutics Reports Promising MNPR-101 Study Results
Mar 05
7:10am ET
Monopar Therapeutics announces preclinical imaging data for MNPR-101
Feb 27
7:13am ET
Monopar Therapeutics Advances Cancer Research with Clinical Trial
Feb 27
7:09am ET
Monopar Therapeutics provides update on MNPR-101-Zr trial
Feb 22
7:23am ET
Monopar Therapeutics announces preclinical data for its MNPR-101 program
Feb 22
7:14am ET
Monopar Therapeutics’ Breakthrough in Advanced Cancer Treatment
Feb 20
8:15am ET
Monopar Therapeutics Advances with Phase 1 Trial Approval
Feb 20
8:06am ET
Monopar receives clearance to proceed with first-in-human trial of MNPR-101-Zr
No recent press releases are available for MNPR
MNPR Financials
Key terms
Ad Feedback
MNPR Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
MNPR Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
